Your session is about to expire
← Back to Search
Olaparib + Temozolomide for Small Cell Lung Cancer
This trial is studying if olaparib and temozolomide may work better in treating patients with small cell lung cancer.
- Small Cell Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2023 Phase 3 trial • 154 Patients • NCT02184195
Awards & Highlights
Find a Location
Who is running the clinical trial?
- Group 1: Olaparib and Temozolomide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is Olaparib's most popular therapeutic use?
"Olaparib is often used to treat patients with advance directives. Olaparib can also help those who have undergone previous chemotherapy, experienced disease progression, or received nitrosourea treatment."
How many people are in this clinical trial?
"Unfortunately, this study is not admitting any more participants at the moment. The trial was first posted on October 13th, 2015 and updated January 24th, 2022. If you are interested in other studies, 1617 trials for small cell lung cancer (sclc) and 407 Olaparib studies are currently looking for patients."
Could you please provide a history of Olaparib clinical trials?
"There are 407 active clinical trials for Olaparib worldwide, with 52 of those in Phase 3. Most studies are located in Phoenix, Arizona; however, there are 13942 total locations running these trials."
Is this research the first to explore this treatment method?
"There are currently 407 ongoing trials for Olaparib in 59 different countries. The first trial was conducted 18 years ago by Schering-Plough and completed its Phase 2 drug approval stage with the help of 60 patients. Since then, 359 more studies have been completed."
Are you currently looking for participants in this trial?
"This clinical trial is no longer recruiting patients. It was originally posted on 10/13/2015 and the last edit was made on 1/24/2022. If you are looking for other trials, there are currently 1617 active clinical trials enrolling patients with small cell lung cancer (sclc) and 407 Olaparib trials actively recruiting participants."
Share this study with friends